Pfizer Inc.
Human cytomegalovirus gB polypeptide
Last updated:
Abstract:
The present invention relates to a polypeptide that includes at least one mutation in the fusion loop 1 region and/or in the fusion loop 2 region and/or in the furin-like cleavage site of a human cytomegalovirus gB polypeptide. In one embodiment, the polypeptide undergoes a structural conformation change in response to pH change.
Status:
Grant
Type:
Utility
Filling date:
9 Mar 2017
Issue date:
7 Apr 2020